Abstract:Histone acetylation modification is governed by the intricate interplay of histone deacetylases (HDACs) and histone acetyltransferases (HATs), where elevated HDAC activity in both neurons and immune cells regulates the expression of genes implicated in pain pathways, promoting neuronal excitability and neuroinflammation, and ultimately, enabling neuropathic pain. Background Neuropathic pain remains a formidable challenge for modern medicine. The first‐line pharmacological therapies exhibit limited efficacy and unfavorable side effect profiles, highlighting an unmet need for effective therapeutic medications. The past decades have witnessed an explosion in efforts to translate epigenetic concepts into pain therapy and shed light on epigenetics as a promising avenue for pain research. Recently, the aberrant activity of histone deacetylase (HDAC) has emerged as a key mechanism contributing to the development and maintenance of neuropathic pain. Aims In this review, we highlight the distinctive role of specific HDAC subtypes in a cell‐specific manner in pain nociception, and outline the recent experimental evidence supporting the therapeutic potential of HDACi in neuropathic pain. Methods We have summarized studies of HDAC in neuropathic pain in Pubmed. Results HDACs, widely distributed in the neuronal and non‐neuronal cells of the dorsal root ganglion and spinal cord, regulate gene expression by deacetylation of histone or non‐histone proteins and involving in increased neuronal excitability and neuroinflammation, thus promoting peripheral and central sensitization. Importantly, pharmacological manipulation of aberrant acetylation using HDAC‐targeted inhibitors (HDACi) has shown promising pain‐relieving properties in various preclinical models of neuropathic pain. Yet, many of which exhibit low‐specificity that may induce off‐target toxicities, underscoring the necessity for the development of isoform‐selective HDACi in pain management. Conclusions Abnormally elevated HDACs promote neuronal excitability and neuroinflammation by epigenetically modulating pivotal gene expression in neuronal and immune cells, contributing to peripheral and central sensitization in the progression of neuropathic pain, and HDACi showed significant efficacy and great potential for alleviating neuropathic pain.

HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice

HDAC6 as a potential therapeutic target for peripheral nerve disorders

Classical HDACs in the Regulation of Neuroinflammation.

Normalizing HDAC2 Levels in the Spinal Cord Alleviates Thermal and Mechanical Hyperalgesia After Peripheral Nerve Injury and Promotes GAD65 and KCC2 Expression

HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1–induced Charcot-Marie-Tooth disease

Therapeutic indications for HDAC6 inhibitors in the peripheral and central nervous disorders

Design, synthesis, and anti-inflammatory activity characterization of novel brain-permeable HDAC6 inhibitors

Comparison of Different Histone Deacetylase Inhibitors in Attenuating Inflammatory Pain in Rats

Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot–Marie–Tooth Disease

Development of a Tetrahydroindazolone-Based HDAC6 Inhibitor with In-Vivo Anti-Arthritic Activity

Identification of Potential Inhibitors of Histone Deacetylase 6 Through Virtual Screening and Molecular Dynamics Simulation Approach: Implications in Neurodegenerative Diseases

Histone deacetylase as emerging pharmacological therapeutic target for neuropathic pain: From epigenetic to selective drugs

HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease

Histone Deacetylase Inhibitor-Induced Emergence of Synaptic Δ-Opioid Receptors and Behavioral Antinociception in Persistent Neuropathic Pain

Inhibition of HDAC6 alleviates cancer‑induced bone pain by reducing the activation of NLRP3 inflammasome

Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

Molecular Imaging Reveals Antineuroinflammatory Effects of HDAC6 Inhibition in Stroke Models

Involvement of HDAC6 in Ischaemia and Reperfusion-Induced Rat Retinal Injury

Spinal Histamine in Attenuation of Mechanical Hypersensitivity in the Spinal Nerve Ligation-Induced Model of Experimental Neuropathy

Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019)

Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury.